June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Risk and Assessment of COVID-19 in a Retina Ophthalmologic Setting
Author Affiliations & Notes
  • Jacobi A Robertson
    University of Wisconsin-Madison, Madison, Wisconsin, United States
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Marwan Abdulaal
    University Hospitals, Cleveland, Ohio, United States
  • Madison T Moore
    University of Maryland Baltimore, Baltimore, Maryland, United States
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Joseph M Coney
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Sean Platt
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Llewelyn J Rao
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • David G Miller
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Scott D Pendergast
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Jerome P Schartman
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Michael A Novak
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Shawn A Lewis
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Matthew K Adams
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Arnold F Nothnagel
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Thomas P Hull
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Thomas J Tsai
    Retina Associates of Cleveland Inc, Beachwood, Ohio, United States
  • Footnotes
    Commercial Relationships   Jacobi Robertson, None; Marwan Abdulaal, None; Madison Moore, None; Joseph Coney, Aerpio (F), Alimera (F), Allergan (F), Apellis (F), Genentech (S), Hoffman La Roache,Ltd (F), MacTel (F), National Eye Institute (F), Notal Vision (F), Ohr (F), Ophthotech (F), Regeneron Pharmaceuticals, Inc. (I), Tyrogenex (F); Sean Platt, None; Llewelyn Rao, None; David Miller, Regeneron (F); Scott Pendergast, None; Jerome Schartman, None; Michael Novak, None; Shawn Lewis, None; Matthew Adams, None; Arnold Nothnagel, None; Thomas Hull, None; Thomas Tsai, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1989. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jacobi A Robertson, Marwan Abdulaal, Madison T Moore, Joseph M Coney, Sean Platt, Llewelyn J Rao, David G Miller, Scott D Pendergast, Jerome P Schartman, Michael A Novak, Shawn A Lewis, Matthew K Adams, Arnold F Nothnagel, Thomas P Hull, Thomas J Tsai; Risk and Assessment of COVID-19 in a Retina Ophthalmologic Setting. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1989.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the risks and impact of COVID-19, SARS-CoV-2, on a private ophthalmology practice in Ohio and analyze the fluctuation in patient visits and surgeries before and during the COVID-19 pandemic.

Methods : A retrospective analysis was performed using outpatient clinic logs for patients seen during the first 10 weeks of 2020 and compared to outpatient clinic logs for 10 weeks during the COVID-19 pandemic. During the twenty-week period, the number of appointments, intravitreal injections, and surgeries, most commonly retinal detachments, epiretinal membrane (ERM), and vitreous hemorrhages, were compared. Additionally, consideration was given to potential measures to reduce the spread and maintain pre-pandemic clinical care levels. The number of appointments, injections administered, and surgeries completed or postponed were analyzed before and during the COVID-19 pandemic. The practice implemented additional precautions for patients and staff. These included, but were not limited to, temperature checks, hand sanitizer availability, required use of face masks, and asking patients to come alone to appointments; with the exception of patients that were wheelchair bound, suffered from dementia, were under the age of 18, or required a translator.

Results : During the first 10 weeks of 2020, the practice saw an average of 2,205 visits a week. In week one of the pandemic, the average was 1,147 patients per week, a 54% drop. An overall 40% drop was seen in surgical cases; vitreous hemorrhage surgeries decreased by 35%, retinal detachment surgeries decreased 25%, and ERM peels reduced by 60%. The drop in ERM’s were mostly due to rescheduling. Intravitreal injections during the first 10 weeks averaged 1,025 (SD±112) per week. During the start of the 10 COVID-19 weeks, intravitreal injections averaged 852 (SD±122) per week and by the last weeks injections averaged 972 (SD±142) per week.

Conclusions : In the early stages, the initial number of outpatient visits declined by 54%, the average number of intravitreal injections did not change in a similar pattern. This represents the importance of patients’ triage and prioritizing urgent cases.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×